CLINICAL_TRIALS
research
· 2014-09-23
Clinical Trial Update: Inhibition of Complement Activation (Eculizumab) in Guillain-Barre Syndrome Study [Phase 2]
Summary
A Phase 2 trial is evaluating eculizumab, a complement inhibitor, for Guillain-Barré syndrome. The current status of the study is unknown.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: NHS Greater Glasgow and Clyde | Conditions: Gullian Barre Syndrome | Phase 2 | Status: UNKNOWN